Author

Jessica Kendall

Observed name: J. Kendall

Observed institution: University of Leeds

ORCID: 0000-0003-2884-4849

Observed ORCID: 0000-0003-2884-4849

OpenAlex ID: A5049587707

CApecitabine plus Radium-223 (Xofigo™) in breast cancer patients with BONe metastases (CARBON): study protocol for a phase IB/IIA randomised controlled trial

2020 · Rob Coleman, Janet Brown, et al. · Trials · 15

PDF

Ixazomib with cyclophosphamide and dexamethasone in relapsed or refractory myeloma: MUKeight phase II randomised controlled trial results

2022 · Holger W. Auner, Sarah R. Brown, et al. · Blood Cancer Journal · 14

PDF

A phase IB and randomised phase IIA trial of CApecitabine plus Radium-223 (Xofigo™) in breast cancer patients with BONe metastases: CARBON trial results

2022 · Matthew Winter, Rob Coleman, et al. · Journal of bone oncology · 11

PDF

Carfilzomib Versus Bortezomib in Combination with Cyclophosphamide and Dexamethasone for Treatment of First Relapse or Primary Refractory Multiple Myeloma (MM): Outcomes Based on Genetic Risk and Long Term Follow up of the Phase 2 Muk Five Study

2018 · Kwee Yong, Samantha Hinsley, et al. · Blood · 6

MUKtwelve protocol: a phase II randomised, controlled, open, parallel group, multicentre trial of selinexor, cyclophosphamide and prednisolone (SCP) versus cyclophosphamide and prednisolone (CP) in patients with relapsed or refractory multiple myeloma

2022 · Jessica Kendall, Andrew Hall, et al. · BMJ Open · 3

PDF

Abstract CT569: Combination of reovirus (pelareorep) and granulocyte-macrophage colony-stimulating factor (GM-CSF) alongside standard chemoradiotherapy and adjuvant chemotherapy (temozolomide) for patients with glioblastoma multiforme (GBM): Long term follow up results of the ReoGlio phase Ib trial

2022 · Susan C. Short, Jessica Kendall, et al. · Cancer Research · 3

Ctim-14. Pelareorep and Granulocyte-macrophage Colony-stimulating Factor (gm-csf) With Standard Chemoradiotherapy/adjuvant Temozolomide for Glioblastoma Multiforme (gbm) Patients: Reoglio Phase I Trial Results

2020 · Jessica Kendall, Anthony Chalmers, et al. · Neuro-Oncology · 3

3513 ATM inhibition with AZD1390 and conventional radiotherapy in non-small cell lung cancer: interim report from the CONCORDE phase Ib trial (NCT04550104)

2025 · Gerard Walls, Ashley Horne, et al. · Radiotherapy and Oncology · 2

Analyzing Patient-Reported Outcome Data in Oncology Care

2024 · Isabella Fornacon-Wood, Thitikorn Nuamek, et al. · International Journal of Radiation Oncology*Biology*Physics · 2

INVEST: A phase Ib window of opportunity study of atezolizumab administered either intravesically or direct tumour injection in patients with bladder cancer prior to radical cystectomy.

2024 · Syed A. Hussain, Jamie B. Oughton, et al. · Journal of Clinical Oncology · 2

PDF

Project Optimus for Radiation Therapy–Drug Combinations: Moving Beyond the Maximum Tolerated Dose

2026 · Alastair Greystoke, Sarah Brown, et al. · International Journal of Radiation Oncology*Biology*Physics · 1

Radiating Excellence: A Decade of Pioneering Radiotherapy Trials and Collaborative Leadership at Leeds Cancer Research UK Clinical Trials Unit

2025 · F. Slevin, E.M. Hudson, et al. · Clinical Oncology · 1

A phase Ib window of opportunity study of atezolizumab administered intravesically or direct injection in patients undergoing radical cystectomy for bladder cancer: Results of the single dose cohorts.

2025 · Syed A. Hussain, Jamie B. Oughton, et al. · Journal of Clinical Oncology · 1

PDF

Olaparib, AZD1390, ceralasertib, saruparib and consolidation durvalumab (CONCORDE) phase Ib platform study of novel DNA damage response inhibitor (DDRi) agents in combination with radiotherapy in non-small cell lung cancer (NSCLC).

2024 · Alastair Greystoke, Jamie B. Oughton, et al. · Journal of Clinical Oncology · 1

Muktwelve: A Randomized Phase II Trial of Selinexor, Cyclophosphamide and Prednisolone Vs Cyclophosphamide and Prednisolone in Relapsed or Refractory Multiple Myeloma (RRMM) Patients

2019 · Sarah R Brown, Andrew Hall, et al. · Blood · 1

INtraVESical immunoTherapy ( INVEST ) prior to radical cystectomy for bladder cancer: trial protocol

2026 · Ruby Lister‐Whelan, Ethan Senior, et al. · British Journal of Urology

PDF

1232: Modern era radical radiotherapy toxicity: a preliminary CONCORDE analysis of the calibration arm

2024 · Ashley Horne, Sarah Brown, et al. · Radiotherapy and Oncology

PDF

CONCORDE: a phase Ib platform study of novel agents in combination with conventional radiotherapy in NSCLC

2023 · Ashley Horne, Sarah Brown, et al. · Lung Cancer

CONCORDE: a phase Ib platform study of novel agents in combination with conventional radiotherapy in non-small cell lung cancer (NSCLC)

2022 · Ashley Horne, Aaisha Ali, et al. · Lung Cancer

PDF

Abstract PS14-02: A randomised phase IB/IIA study of CApecitabine plus Radium-223 in breast cancer patients with BONe metastases (CARBON) - Safety and preliminary efficacy findings

2021 · Matthew Winter, Jessica Kendall, et al. · Cancer Research

Works count: 20

Citation count: 66

H-index: 4

I10-index: 3